P. Hermann

发表

Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran

D. Chassard, C. Puozzo, P. Hermann, 2006, International clinical psychopharmacology.

Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic

P. Hermann, J. Desager, C. Harvengt, 1988, Psychopharmacology.

Zolpidem excretion in breast milk

G. Bianchetti, P. Hermann, J. Thénot, 2004, European Journal of Clinical Pharmacology.

Determination of betaxolol, a new beta-blocker, by gas chromatography mass spectrometry: application to pharmacokinetic studies.

P. Hermann, P. Morselli, J. Thénot, 1984, Biomedical mass spectrometry.

Pharmacokinetics of diltiazem and other calcium entry blockers.

P. Hermann, P. Morselli, 2009, Acta pharmacologica et toxicologica.

Pharmacokinetics and antipyretic effects of an injectable pro‐drug of paracetamol (propacetamol) in children

P. Hermann, C. Saint-Maurice, J. Granry, 1992 .

Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo.

Georges Houin, G. Houin, P. Hermann, 2004, International journal of pharmaceutics.

Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans. A possible model to account for multiple plasma peaks.

G. Houin, I. Carrié, P. Hermann, 1998, Arzneimittel-Forschung.

Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats

Laishun Chen, P. Hermann, L. Roques, 2015, Drug design, development and therapy.

Pharmacokinetics of diltiazem after intravenous and oral administration

D. London, P. Hermann, P. Morselli, 2004, European Journal of Clinical Pharmacology.

Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine.

P. Hermann, J. Desager, C. Harvengt, 1988, International journal of clinical pharmacology research.

Kinetics of an injectable pro-drug of acetaminophen (propacetamol) in children

P. Hermann, J. Granry, J. Merckx, 1991 .